Editor's Note

Q4 revenues rose +124% and they are guiding for another 100% rise in 2018. Positive drug news and new approvals are boosting Corcept.


New positions are only added on Wednesday and Saturday except in special circumstances.


CORT - Corcept Therapeutics - Company Profile

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California. Company description from FinViz.com.

Earnings May 24th.

The company reported Q4 earnings of 17 cents that missed estimates for 19 cents. However, revenue rose to 53.3 million to bring 2017 total revenue up to $159.2 million. They guided for the full year for revenue ot $275-$300 million, up from $158.2 million in 2017 with profits of $129.1 million. That is a really strong ratio. If thye can hit their target for 2018 the profits are also going to double.

This is a real simple position. The company is guiding for a 100% growth in revenue and the shares are breaking out of a double bottom over the last month.

Buy CORT shares, currently $18.26, initial stop loss $17.00.
Alternate position: Buy May $20 call, currently $1.15. No initial stop loss.


No New Bearish Plays